Celcuity (CELC) Is Up 7.6% After FDA Accepts Gedatolisib Application for Expedited Review - What's Changed [Yahoo! Finance]
Celcuity Inc. (CELC)
Last celcuity inc. earnings: 3/12 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
celcuity.com/home/investors
Company Research
Source: Yahoo! Finance
Food and Drug Administration for gedatolisib, targeting hormone receptor positive, HER2 negative advanced breast cancer, under the Real-Time Oncology Review program. This milestone follows Breakthrough Therapy and Fast Track designations for gedatolisib, underscoring the regulatory momentum behind Celcuity's lead oncology candidate. We'll explore how the FDA's expedited review of gedatolisib could alter Celcuity's investment narrative as it advances in oncology drug development. Outshine the giants: these 27 early-stage AI stocks could fund your retirement What Is Celcuity's Investment Narrative? To be a shareholder in Celcuity right now, you'd need to have high conviction in the company's ability to turn its promising drug pipeline, especially gedatolisib, into approved and commercially viable oncology therapies. The recent New Drug Application submission to the FDA for gedatolisib under the Real-Time Oncology Review program marks a potential acceleration of Celcuity's most
Show less
Read more
Impact Snapshot
Event Time:
CELC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CELC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CELC alerts
High impacting Celcuity Inc. news events
Weekly update
A roundup of the hottest topics
CELC
News
- Celcuity (NASDAQ:CELC) had its price target raised by analysts at Jefferies Financial Group Inc. from $108.00 to $134.00. They now have a "buy" rating on the stock.MarketBeat
- Celcuity (CELC): Assessing Valuation Following Recent Share Price Surge [Yahoo! Finance]Yahoo! Finance
- Celcuity: From Speculative Bet To Pre-Commercial Powerhouse [Seeking Alpha]Seeking Alpha
- This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results [Yahoo! Finance]Yahoo! Finance
- Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium [Yahoo! Finance]Yahoo! Finance
CELC
Earnings
- 11/12/25 - Beat
CELC
Sec Filings
- 12/3/25 - Form 4
- 12/1/25 - Form 144
- 11/24/25 - Form 4
- CELC's page on the SEC website